Monitoring Hepatitis C

Similar documents
HCSP TRAINING MANUAL

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

Module 1 Introduction of hepatitis

Review: How to work up your patient with Hepatitis C

Transmission of HCV in the United States (CDC estimate)

La b o r at o ry Test s a n d Pr o c e d u r e s

Liver 102: Injury and Healing

Hepatitis C Virus (HCV)

A Rational Evidence-based Approach to Abnormal Liver Tests

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

Laboratory and Clinical Diagnosis of HCV Infection

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Patterns of abnormal LFTs and their differential diagnosis

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

Hepatitis C Information Sheet.

Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

Pretreatment Evaluation

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis

What is Hepatitis C Virus (HCV)?

Primary Biliary Cholangitis

Patterns of abnormal LFTs and their differential diagnosis

Chronic Hepatitis C. Risk Factors

Abnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University

Physical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford

Xiao-Ling Chi, Mei-Jie Shi, Huan-Ming Xiao, Yu-Bao Xie, and Gao-Shu Cai. Correspondence should be addressed to Xiao-Ling Chi;

ROUTINE LAB STUDIES. Routine Clinic Lab Studies

The Future is Here Now!

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Hepatology For The Nonhepatologist

GI Workshop Case Studies

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Management of Acute HCV Infection

Routine Clinic Lab Studies

Hepatitis A, B, C Hepatitis A Hepatitis B Hepatitis C For Internal Use Only. Not For Use With The Public.

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Hepatitis C Update on New Treatments

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor

Section 3: Testing and Diagnosis of Hepatitis C

EVALUATION OF ABNORMAL LIVER TESTS

Interpreting Liver Function Tests

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques

Pathophysiology I Liver and Biliary Disease

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Hepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE

DIABETES AND LABORATORY TESTS. Author: Josephine Davis

Break the Liver Biopsy Habit

Hepatitis C: Surveillance, Case Definition, and Investigation

Understanding Blood Tests

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

IMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C

Hepatitis C January 26, 2018

HPI (2006) Question: Douglas T. Dieterich, MD. What is the risk of mother-to-child transmission in HCV for this woman?

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

Clinical cases: HIV/HCV coinfection

The New World of HCV Therapy

Non-Invasive Testing for Liver Fibrosis

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Toronto Declaration 2014: Global Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

FACTS AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES

Pretreatment Evaluation

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

Pretreatment Evaluation

Evaluation on liver fibrosis stages using the k-means clustering algorithm

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

HEPATITIS C. The Facts

Part I. Prior Authorization Criteria and Policy

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Treatment for Hepatitis B

MP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016

The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Chronic hepatitis B virus (HBV)

Updates in the Treatment of Hepatitis C

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a

Observational Medical Outcomes Partnership

GI DISEASE WORKSHOP CASE STUDIES

Investigating and Referring Incidental Findings of Abnormal Liver Tests

Interpreting Your Tests

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse

Clinician Blood Panel Results

HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM

Molina Healthcare of Texas Hepatitis C Drugs (Medicaid)

World Health Organization. Western Pacific Region

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK

Transcription:

Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody test followed by a confirmatory HCV viral load test. Once hepatitis C is diagnosed, ongoing monitoring is needed to assess disease progression and the need for treatment. It is recommended that you use the same laboratory for all of your tests, since result ranges and accuracy can vary from lab to lab. Keep copies of your lab and biopsy results for future reference. HCV Antibody Tests: Antibody tests measure proteins produced by the immune system to fight specific invaders. After exposure to HCV, it may take up to 26 weeks (the window period ) before antibodies can be detected using a standard test.

Viral Load Tests: Viral load tests measure the amount of HCV RNA circulating in the blood. The presence of detectable genetic viral material indicates that the virus is actively replicating. HCV viral load is expressed as International Units (IU/mL). There are three different types of viral load tests: HCV RNA polymerase chain reaction (PCR), branched-chained DNA (bdna), and transcription mediated amplification (TMA). The PCR and TMA tests can detect viral loads as low as 5 IU/mL. The bdna assay has a lower limit of detection of 615 IU/mL. Viral load tests are used to confirm active HCV infection, to measure how well medications are working against the virus, and to establish whether someone has been cured of hepatitis C. The association between viral load and disease progression has not been established in other words a high or low viral load does not translate into better or worse liver damage.

HCV Genotype Tests: Genotype tests are used to determine what type(s) also called strains of HCV an individual carries. This information is used to decide on the medications used to treat hepatitis C. There are 7 genotypes numbered 1 through 7. HCV Genotype 1 is the most common genotype (70-75%) in the United States followed by genotypes 2 and 3 (25-30%). The other genotypes are not as prevalent in the United States. Biochemical or Liver Function Tests: Various blood tests are used to assess how well the liver is working. Many of these tests measure non-specific markers of liver function. Liver enzyme tests are part of a hepatic panel (a group of clinical laboratory blood tests used to evaluate a patient with symptoms of liver disease or injury). The most common measurements of liver

inflammation are alanine aminotransferase (ALT, formerly known as SGPT) and aspartate aminotransferase (AST, formerly known as SGOT). ALT and AST are enzymes released into the blood when liver cells are damaged. They are often but not always elevated in people with hepatitis C. Many individuals with hepatitis C infection have mild to moderate ALT and AST elevation, which is often the first indication that they are infected. In the past, ALT levels were assumed to be a marker of disease progression due to hepatitis C, but it is now known that some people with chronic hepatitis C experience serious liver disease progression with relatively normal ALT levels. This is why it is important for people with HCV to be monitored with a variety of tests, which may include a liver biopsy or a Fibroscan. Other measurements of liver inflammation include alkaline phosphatase (ALK) and gamma-glutamyl transpeptidase (GGT). Abnormal levels may indicate cirrhosis or bile duct blockage, as well as other conditions. In addition, your doctor may measure INR (international normalized ratio, formally known as PT or prothrombin time, an indication of blood clotting speed), albumin and bilirubin levels. Albumin is a blood protein produced by the liver that plays a role in maintaining normal blood volume. Bilirubin is a pigment that is often present in the blood of people with liver inflammation; high bilirubin levels result in jaundice. Many factors, such as the use of medications and alcohol, can cause abnormal lab

results. Before drawing your own conclusions about the meaning of a test result, check with a healthcare provider. Fibroscan: This test is an alternative to the liver biopsy to assess the level of liver damage. The Fibroscan is usually combined with other liver biochemical blood tests to better gauge liver damage. Liver Biopsy: Liver biopsies are done to evaluate the severity of inflammation, amount of fibrosis or scarring, and general health of the liver. A biopsy may be used to help determine if treatment is needed that is, if significant liver damage is present and serial biopsies are used to assess disease progression over time. The most common procedure is called a percutaneous (through the skin) liver biopsy, in which the skin and muscle near the liver are numbed and a needle is quickly inserted into the liver to draw out a specimen. Many people fear this procedure, but complications are rare. If you are anxious, ask your physician for a mild tranquilizer prior to your biopsy and for pain medication afterwards. Experimental Noninvasive Fibrosis Tests: In recent years researchers have developed several noninvasive methods of assessing fibrosis, in an effort to avoid the discomfort and expense of repeat biopsies. Experts have evaluated the accuracy of several combinations of biomarkers and patient

characteristics, including FibroSure, APRI, Fib-4, Forns index, and FibroTest. Noninvasive methods are reasonably accurate in providing information about the amount of liver damage. Self-Help Tips: Medical History List your illnesses and surgeries. Start with the most recent and work backwards. Try to list only the conditions, diseases, or surgeries that are important for your provider to know. Be honest your provider can not advise and guide you if you are hiding information. Many people feel like they will be judged if they report that they smoke, drink or take drugs. However, it is important for your provider to know about these things in order to guide you and keep you healthy. Be truthful about your feelings. If you are concerned that you might get lectured, talk about it with your provider. If possible, review your medical history and records once a month and thoroughly at least once a year. Next: Hepatitis C Medications and Treatment Response Terms